Metronomic anti-cancer therapy – an ongoing treatment option for advanced cancer patients
Authors:
- K MrossKMK Mross
- S SteinbildSSS Steinbild
Open Access
- 1 January 2012
- journal article
- Published by Herbert Publications PVT LTD in journal of Cancer Therapeutics and Research
- Vol. 1 (1) , 32
Abstract
The therapeutic concept of administering agents (cytotoxic/-static,non-cytotoxic and/or targeted drugs) continuously at lower doses - relative to MTDs in the case of cytostatic and cytotoxic drugs or continuously at tolerableKeywords
This publication has 108 references indexed in Scilit:
- An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II studyCancer Chemotherapy and Pharmacology, 2011
- Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerBritish Journal of Cancer, 2011
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphomaCancer, 2010
- A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanomaCancer, 2010
- Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyBritish Journal of Cancer, 2009
- A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patientsBritish Journal of Cancer, 2008
- Immunological aspects of cancer chemotherapyNature Reviews Immunology, 2008
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonistsThe Lancet Oncology, 2004